Novartis India Ltd
Novartis India Ltd (NOVARTIND) is scheduled to report results on 3 Nov 2026. Novartis India Ltd last reported results for the quarter ended Jun 2026, with sales of ₹104 crore and net profit of ₹32 crore. The stock last traded at ₹2,049, a market capitalisation of ₹5,062 crore, on a P/E of 51.8. Over the past 52 weeks the stock has ranged between ₹750 and ₹2,589. Figures are as of 9 Oct 2026 and are not real time.
Novartis India Ltd share price and key metrics
- Current price
- ₹2,049
- Market cap
- ₹5,062 cr
- Stock P/E
- 51.8
- Book value
- ₹331
- ROE
- 11.6%
- ROCE
- 16.3%
- Dividend yield
- 0.00%
- 52w high / low
- 2589/750
Metrics as of 9 Oct 2026. Not real time.
Track Novartis India Ltd
Cruxal reads every Novartis India Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Novartis India Ltd growth and returns
- 10 Years
- -6%
- 5 Years
- -1%
- 3 Years
- -2%
- TTM
- 5%
- 10 Years
- -7%
- 5 Years
- 35%
- 3 Years
- -3%
- TTM
- -5%
- 10 Years
- 11%
- 5 Years
- 20%
- 3 Years
- 42%
- 1 Year
- 134%
- 10 Years
- 8%
- 5 Years
- 11%
- 3 Years
- 12%
- Last Year
- 12%
Novartis India Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹104 cr, up 18.2% from ₹88 cr a year earlier. Net profit was ₹32 cr, up 14.3% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 87 | 93 | 84 | 88 | 90 | 86 | 91 | 104 |
| Expenses | 69 | 67 | 60 | 60 | 66 | 64 | 70 | 69 |
| Operating profit | 18 | 26 | 24 | 27 | 24 | 22 | 21 | 35 |
| OPM % | 21% | 28% | 29% | 31% | 26% | 26% | 23% | 34% |
| Other income | 10 | 11 | 11 | 11 | 9 | 9 | 10 | 9 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Profit before tax | 28 | 35 | 34 | 37 | 33 | 30 | 30 | 43 |
| Tax % | 26% | 28% | 14% | 26% | 26% | 46% | 16% | 25% |
| Net profit | 20 | 25 | 29 | 28 | 24 | 16 | 25 | 32 |
| EPS (₹) | 8.27 | 10.31 | 11.87 | 11.19 | 9.81 | 6.52 | 10.23 | 13.05 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Novartis India Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 656 | 564 | 491 | 438 | 381 | 400 | 379 | 335 | 356 | 354 | 371 |
| Operating profit | 25 | -6 | 12 | 12 | 27 | 27 | 65 | 65 | 91 | 94 | 102 |
| OPM % | 3.8% | -1.1% | 2.5% | 2.8% | 7% | 7% | 17% | 19% | 26% | 27% | 27% |
| Net profit | 57 | 78 | 52 | 10 | 21 | -4 | 103 | 85 | 101 | 93 | 98 |
| EPS (₹) | 20.33 | 31.74 | 20.97 | 4.08 | 8.46 | -1.51 | 41.86 | 34.50 | 40.87 | 37.74 | 39.61 |
TTM is the trailing twelve months to the most recent quarter.
Novartis India Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 14 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 906 | 721 | 747 | 708 | 699 | 679 | 763 | 732 | 773 | 805 |
| Borrowings | 0 | 0 | 0 | 68 | 62 | 24 | 22 | 7 | 5 | 3 |
| Other liabilities | 230 | 377 | 223 | 289 | 229 | 242 | 186 | 173 | 158 | 157 |
| Total liabilities | 1,150 | 1,111 | 982 | 1,078 | 1,002 | 958 | 983 | 925 | 948 | 978 |
| Fixed assets | 6 | 5 | 15 | 76 | 64 | 24 | 19 | 7 | 5 | 3 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 1,144 | 1,106 | 967 | 1,001 | 938 | 934 | 964 | 918 | 943 | 975 |
| Total assets | 1,150 | 1,111 | 982 | 1,078 | 1,002 | 958 | 983 | 925 | 948 | 978 |
As reported by the company. Total assets equal total liabilities by construction.
Novartis India Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -41 | 161 | -194 | -23 | -69 | 39 | 45 | 113 | 75 | 47 |
| Cash from investing | 424 | 69 | 274 | 56 | 95 | 87 | -153 | 33 | -3 | 18 |
| Cash from financing | -332 | -268 | -30 | -41 | -37 | -36 | -30 | -121 | -64 | -64 |
| Net cash flow | 51 | -38 | 50 | -9 | -11 | 90 | -139 | 26 | 7 | 0 |
| Free cash flow | -44 | 160 | -208 | -24 | -69 | 38 | 45 | 113 | 75 | 46 |
| CFO / operating profit | 13% | -3,503% | -1,210% | 124% | -127% | 210% | 65% | 115% | 99% | 87% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Novartis India Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 9% | 17% | 12% | 5% | 6% | 6% | 15% | 16% | 17% | 16% |
| Debtor days | 23 | 28 | 34 | 31 | 37 | 41 | 35 | 45 | 41 | 38 |
| Inventory days | 104 | 84 | 111 | 117 | 119 | 117 | 99 | 82 | 74 | 98 |
| Days payable | 87 | 158 | 168 | 145 | 137 | 148 | 108 | 112 | 93 | 101 |
| Cash conversion cycle | 40 | -45 | -23 | 3 | 19 | 10 | 26 | 15 | 22 | 36 |
| Working capital days | -14 | -99 | 7 | -1 | 62 | -23 | -37 | -59 | -45 | -46 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Novartis India Ltd shareholding pattern
Promoters held 70.68% at Jul 2026, broadly unchanged since Sep 2025. FIIs 0.15% and DIIs 1.39%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% |
| FIIs | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.17% | 0.16% | 0.15% |
| DIIs | 0.53% | 0.53% | 0.53% | 0.53% | 0.63% | 0.53% | 1.35% | 1.39% |
| Public | 28.60% | 28.61% | 28.60% | 28.61% | 28.50% | 28.60% | 27.81% | 27.79% |
| No. of shareholders | 38,926 | 39,133 | 39,040 | 39,353 | 39,468 | 38,116 | 36,502 | 36,706 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Novartis India Ltd’s next results date?
Novartis India Ltd’s next results are scheduled for 3 Nov 2026.
- Board meetingApproval of unaudited financial results for quarter and half year ended September 30, 2026
See the full results calendar for every Indian company reporting in the next 30 days.
Cruxal coverage of Novartis India Ltd
Evonile Pharma board approves rights issue of up to Rs 900 crore
Evonile Pharma (formerly Novartis India) board okays a partly paid-up equity rights issue of up to Rs 900.00 cr; record date and pricing to be set later.
Novartis India Ltd3 min
Novartis India shares fall 3.3% as routine AGM proceedings trigger profit-booking
Novartis India shares slipped 3.3% to Rs 1,960 after the company’s AGM proceedings filing delivered routine governance approvals but no fresh catalysts, prompting profit-booking after a sharp prior rally.
Novartis India Ltd5 minNovartis India Ltd corporate filings
- Evonile Pharma Limited Approves Rights Issue of ₹9,000 crore to Raise CapitalBoard Meetinghigh impact
Cruxal's analysis: Evonile Pharma Limited has announced the approval of a rights issue to raise up to ₹9,000…
Read the full analysis - Evonile Pharma Limited receives stable credit ratings from CARE Ratings for its bank facilities, indicating a positive outlook on its creditworthinessCompany Updatemedium impact
Cruxal's analysis: Evonile Pharma Limited, formerly Novartis India Limited, has been assigned a long-term…
Read the full analysis - Evonile Pharma Limited schedules Board meeting on October 8, 2026, to consider raising funds via rights issue of ₹5 face value equity sharesBoard Meetingmedium impact
Cruxal's analysis: Evonile Pharma Limited, formerly Novartis India Limited, has announced a Board meeting…
Read the full analysis - Novartis India Ltd updates Memorandum & Articles of Association; no financial impact indicatedCompany Updatelow impact
Cruxal's analysis: Novartis India Ltd announced amendments to its Memorandum and Articles of Association on…
Read the full analysis - Novartis India Ltd changes name to Evonile Pharma, effective October 1, 2026Company Updatelow impact
Cruxal's analysis: The company, currently valued at approximately 4,777 crore with a market price of 1959…
Read the full analysis - Novartis India Limited schedules Board meeting to consider and approve September 2026 quarter and half-year financial results, with trading window closure from October 1, 2026Board Meetingmedium impact
Cruxal's analysis: Novartis India Limited has announced a scheduled Board meeting on November 3, 2026, to…
Read the full analysis - Intimation of the closure of Trading WindowInsider Trading / SASTlow impact
- Novartis India Limited to Rebrand as Evonile Pharma Limited Following Shareholder Approval at 78th AGMAGM/EGMhigh impact
Cruxal's analysis: Novartis India Limited has received shareholder approval at its 78th Annual General…
Read the full analysis - Novartis India Limited Announces Name Change and Approval of ESOP 2026 at 78th AGMAGM/EGMmedium impact
Cruxal's analysis: Novartis India Limited has concluded its 78th Annual General Meeting, where shareholders…
Read the full analysis - Novartis India to participate in Nuvama Emerging India CEO Forum on September 28, 2026Company Updatelow impact
Cruxal's analysis: Novartis India Ltd has announced that company officials will participate in the 'Emerging…
Read the full analysis - Novartis India Ltd publishes corrigendum for 78th Annual General Meeting noticeCompany Updatelow impact
Cruxal's analysis: Novartis India Ltd has issued a newspaper publication regarding a corrigendum filed on…
Read the full analysis - Novartis India Limited issues corrigendum to AGM notice regarding ESOP 2026 scheme detailsAGM/EGMlow impact
Cruxal's analysis: Novartis India Limited has issued a corrigendum to its 78th Annual General Meeting notice…
Read the full analysis - Novartis India Ltd releases transcript of analyst and institutional investor call held on September 11, 2026Company Updatelow impact
Cruxal's analysis: Novartis India has filed the transcript of its analyst and institutional investor meeting…
Read the full analysis - Novartis India Ltd releases audio recording of investor/analyst call held on September 11, 2026Company Updatelow impact
Cruxal's analysis: Novartis India Ltd has filed the audio recording of the investor and analyst conference…
Read the full analysis - Novartis India Limited Outlines Strategic Transformation and Growth Roadmap Following ChrysCapital AcquisitionCompany Updatehigh impact
Cruxal's analysis: Novartis India Limited (NIL) has unveiled a comprehensive strategic roadmap following its…
Read the full analysis - Novartis India Ltd: Physical dispatch of Annual Report for FY 2025-26 to non-email shareholdersCompany Updatelow impact
Cruxal's analysis: Novartis India Ltd has issued an intimation under Regulation 36(1)(b) of SEBI LODR…
Read the full analysis - Novartis India Ltd schedules investor and analyst meeting for September 11, 2026Company Updatelow impact
Cruxal's analysis: Novartis India Ltd has announced an investor and analyst meeting scheduled for Friday…
Read the full analysis - Novartis India enters into exclusive promotion and distribution agreement for retina portfolioCompany Updatemedium impact
Cruxal's analysis: Novartis India Ltd has entered into an exclusive promotion and distribution agreement…
Read the full analysis - Novartis India Limited to acquire 'Minipress' trademarks from Pfizer for INR 1,250.00 croreCompany Updatehigh impact
Cruxal's analysis: Novartis India Limited has entered into an asset purchase agreement to acquire the…
Read the full analysis - Novartis India Ltd announces 78th Annual General Meeting scheduled for September 24, 2026Company Updatelow impact
Cruxal's analysis: Novartis India Ltd has published a newspaper notice in Financial Express and Navshakti on…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.